**Core tip:** In patients with cirrhosis treated with traditional nonselective beta-blockers (NSBBs) (*i.e*. propranolol and nadolol), the lack of acute hemodynamic response to intravenous propranolol has been consistently associated with a higher risk of decompensation and death. Moreover, carvedilol is more effective than traditional NSBB in reducing portal pressure. In the present study, we evaluated for the first time the clinical impact of an acute hemodynamic response-guided protocol for the primary prophylaxis of variceal bleeding in which acute hemodynamic responders were treated with traditional NSBB and acute nonresponders with carvedilol. Importantly, the risk of decompensation and survival were similar in both groups, strongly suggesting that carvedilol improved the long-term outcome of acute nonresponders.

INTRODUCTION
============

The natural history of cirrhosis is marked by the clinical manifestations of portal hypertension, the most important being variceal bleeding, ascites, spontaneous bacterial peritonitis and hepatic encephalopathy. Their absence or presence defines the two main prognostic stages of liver cirrhosis: compensated and decompensated cirrhosis\[[@B1]\]. Current guidelines emphasize that the goal of treatment in the former is to prevent the development of any type of complication (*i.e*. first decompensation), whereas in the latter the objective should be the prevention of an additional complication (*i.e*. further decompensation) and the improvement of survival\[[@B1],[@B2]\]. Studies in primary and secondary prophylaxis of variceal bleeding have shown that these goals can be achieved by decreasing portal pressure, assessed by the hepatic venous pressure gradient (HVPG), to \< 12 mmHg or 20% from baseline after chronic treatment with nonselective beta-blockers (NSBBs)\[[@B3]-[@B5]\]. In the setting of primary prophylaxis, a lower decrease of at least 10% is also clinically relevant and is a better cutoff to define hemodynamic response\[[@B6],[@B7]\].

Traditional NSBBs (*i.e*. propranolol and nadolol) and carvedilol are valid first-line treatments in patients starting primary prophylaxis of variceal bleeding\[[@B1]\]. Although no clinical trial has adequately compared their efficacy head-to-head, several randomized controlled trials\[[@B8],[@B9]\] and a meta-analysis have shown that carvedilol is more effective in reducing HVPG\[[@B10]\]. These enhanced effects on portal pressure reduction are due to a fall in both intrahepatic and portal-collateral resistance through its intrinsic anti-α-1-adrenergic activity\[[@B11]\]. Confirmation of the chronic hemodynamic response to NSBB requires measuring the HVPG at baseline and after chronic treatment with NSBB\[[@B1]\]. The acute hemodynamic test \[*i.e*. HVPG response after 20 min of the intravenous (i.v.) injection of 0.15 mg/kg propranolol\], however, has been proposed as a valid and more cost-effective alternative to separate HVPG procedures\[[@B1],[@B2]\].

Supporting this notion, recent studies in patients treated with traditional beta-blockers showed that the risk of decompensation was lower in those who had an acute response than in those who were acute nonresponders\[[@B6],[@B7],[@B12]\]. The acute test also predicted the chronic hemodynamic response, thereby enabling the earlier identification of nonresponders who might benefit from a treatment adjustment. Despite the potential advantages, the role of the acute hemodynamic response to guide therapy has never been assessed in the setting of primary prophylaxis of variceal bleeding and only scarcely in other conditions\[[@B13],[@B14]\].

Based on the greater efficacy of carvedilol for reducing HVPG and the potential utility of the acute hemodynamic response to guide therapy, we implemented a protocol for primary prophylaxis of variceal bleeding in our institution in which acute responders were treated with traditional NSBB and acute nonresponders with carvedilol. The aim of the present study was to compare the risk of first or further decompensation of cirrhosis in each group since the implementation of the protocol in 2012.

MATERIALS AND METHODS
=====================

Study cohort
------------

We retrospectively reviewed all the hemodynamic studies performed in our Gastroenterology and Hepatology Department between February 2012 and January 2017. Potential candidates were those referred for a baseline hemodynamic study before the initiation of primary prophylaxis of variceal bleeding. The inclusion criteria were as follows: definitive diagnosis of cirrhosis (based on histology or by unequivocal clinical and radiological findings), baseline HVPG values ≥ 12 mmHg, presence of gastroesophageal varices without any previous episode of variceal bleeding, and evaluation of the acute HVPG response to i.v. propranolol. Patients were excluded if they had contraindication to NSBB, splanchnic venous thrombosis, history of surgery for portal hypertension (including transjugular intrahepatic portosystemic shunt), congestive liver, acute-on-chronic liver failure, liver transplantation or hepatocellular carcinoma at stages C or D of the Barcelona-Clinic Liver Cancer staging system. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki (6^th^ revision, 2008) as reflected in *a priori* approval by the Clinical Research Ethics Committee of Cantabria. A waiver of informed consent was provided since the study was considered a retrospective review.

Hemodynamic measurements
------------------------

Hemodynamic studies were performed as previously described\[[@B15]\]. Briefly, after an overnight fast a catheter introducer was placed under local anesthesia in the right internal jugular vein using the Seldinger technique and was used to advance a 7-F balloon-tipped catheter into the right hepatic vein and a Swan-Ganz catheter into the pulmonary artery under fluoroscopic guidance. The occluded position was confirmed by the absence of reflux after injection of contrast medium. Free hepatic venous pressure was measured in the right hepatic vein close to the inferior vena cava. Portal pressure gradient was measured as the HVPG, which is the difference between the wedged and free hepatic venous pressures. All intravascular pressure measurements were performed in triplicate using a previously calibrated, highly sensitive transducer, with external zero at the mid-axillary line. A permanent recording of tracings was obtained. Electrocardiography, arterial pressure, heart rate, and oxygen saturation were monitored noninvasively throughout the study with an automatic monitor. After completing baseline hemodynamic measurements, a single intravenous bolus of propranolol was administered (0.15 mg/kg) over 5 min. Twenty minutes later, the HVPG response was assessed as previously described\[[@B6],[@B12]\].

Definitions of hemodynamic response
-----------------------------------

Acute or chronic hemodynamic response was defined as a decrease in HVPG to \< 12 mmHg or as a ≥ 10% reduction in HVPG from baseline, as recommended by the Baveno VI consensus\[[@B2]\].

Treatment protocols and drug titration
--------------------------------------

According to our institutional protocol, acute responders were treated with propranolol or nadolol (*i.e*. traditional NSBBs) and nonresponders with carvedilol. After the baseline hemodynamic study, propranolol (20 mg *b.i.d*.), nadolol (20 mg *q.d*.) or carvedilol (6.25 mg *q.d*.) were given orally. If tolerated, the dose was subsequently increased until the resting heart rate descended to 55 beats/min, systolic pressure decreased below 90 mmHg, or the maximum dose was reached (160 mg *b.i.d*. for propranolol, 160 mg *q.d*. for nadolol, and 6.25 mg *b.i.d*. for carvedilol). In patients with concomitant arterial hypertension, carvedilol could be increased up to 12.5 mg *b.i.d*.

Follow-up
---------

Patients were followed-up according to the standardized protocols of our unit. Briefly, they were attended in the outpatient clinic within 1 mo after the performance of the baseline hemodynamic study, and every 3-6 mo thereafter. Medical history, laboratory values, imaging tests and treatment compliance (including abstinence from alcohol) were recorded in each visit. Follow-up data were collected until July 2017, death or liver transplantation.

Objectives and definitions
--------------------------

The primary endpoint was development of first or further decompensation of cirrhosis. Decompensation was defined when gastrointestinal bleeding owing to portal hypertension, ascites, hepatorenal syndrome, spontaneous bacterial peritonitis, or hepatic encephalopathy occurred. Bleeding from esophagogastric varices or portal hypertensive gastropathy was defined according to Baveno VI criteria\[[@B2]\]. Ascites was defined as *de novo* in patients who had never been diagnosed with ascites before or as worsening of preexisting ascites in patients requiring a sustained increase in diuretic dose or large-volume paracentesis. In all cases, it was confirmed by ultrasound and/or paracentesis. Spontaneous bacterial peritonitis was defined following current guidelines\[[@B16]\] and hepatic encephalopathy was diagnosed on clinical basis.

Secondary endpoints included death from any cause, association between acute and chronic hemodynamic response, and baseline clinical and laboratory variables related to the acute hemodynamic response.

Statistical analysis
--------------------

Quantitative variables were expressed as mean ± standard deviation (SD) and qualitative variables as proportions. Comparisons between groups were performed with unpaired Student's *t*-test, Mann-Whitney test or the Fisher's exact test as appropriate. The correlation between acute and chronic changes in HVPG was estimated by the Pearson correlation coefficient, whereas the number of patients correctly and incorrectly classified by the acute HVPG response with respect to the chronic response was compared with the McNemar's test. The adjusted association with the acute hemodynamic response was evaluated by logistic regression analysis introducing variables that were considered related (*P* \< 0.1) in a univariate analysis or clinically significant regardless of the *P* value. The strength of the association of each variable with the acute response was estimated by the odds ratio (OR) with its 95% confidence interval (CI). The actuarial probabilities in patients treated with traditional NSBB and those treated with carvedilol were calculated according to the Kaplan-Meier method and compared using the log-rank test.

Per protocol analysis was performed, as patients not treated with medical therapy according to our institutional protocol were excluded from the analysis. Follow-up was censored at the date of the analyzed event, liver transplantation or death. Patients undergoing liver transplantation were censored as alive, and patients lost to follow-up were censored as free of the analyzed event the day of the last visit. The adjusted association with the risk of reaching the endpoint was investigated with the Cox proportional hazards regression analysis, by introducing covariates that were related (*P* \< 0.1) in univariate analysis or that were considered clinically significant regardless of the *P* value. The contribution of each variable to the risk of reaching the endpoint was estimated by the hazard ratio (HR) with its 95%CI. *P* \< 0.05 was considered statistically significant. The maximum number of variables included in the multivariable analysis was 1 per 5-10 outcomes. Statistical analysis was performed with IBM SPSS Statistics v22.0 for Mac (IBM Corp., Armonk, NY, United States) and GraphPad Prism v6.00 for Mac OS X (GraphPad Software, San Diego, CA, United States).

RESULTS
=======

Four hundred and thirty-eight hemodynamic studies were performed in 309 patients during the study period. The hemodynamic study was performed in the context of evaluation of primary prophylaxis of variceal bleeding in 150 patients. Seventy-four of these patients were not included in the study because they did not fulfill inclusion criteria (*n* = 35), they presented exclusion criteria (*n* = 15), or they did not follow the guided-therapy protocol for diverse reasons (*n* = 24) (see flowchart in Figure [1](#F1){ref-type="fig"}). Of the 76 patients that were valid for the analysis, 52 patients (68.4%) had an acute hemodynamic response to i.v. propranolol and received traditional NSBB for primary prophylaxis, and 24 patients (31.6%) did not have an acute hemodynamic response to i.v. propranolol and received carvedilol. Mean duration of follow-up was similar in both groups (traditional NSBB: 21.8 ± 13.1 mo *vs* carvedilol: 24.1 ± 14.9 mo; *P* = 0.51).

![Flowchart of the study selection process. HVPG: Hepatic venous pressure gradient; NSBB: Nonselective beta-blockers.](WJCC-6-611-g001){#F1}

Predictors of the acute hemodynamic response to i.v. propranolol
----------------------------------------------------------------

There were no clinical, laboratory, endoscopic, or hemodynamic variables capable of predicting the acute hemodynamic response to i.v. propranolol, neither in the univariate analysis (Table [1](#T1){ref-type="table"}) nor in a multivariable analysis, including variables occasionally related with the acute hemodynamic response to i.v. propranolol in prior studies\[[@B17]-[@B19]\]. In particular, the acute hemodynamic response was not associated with the etiology of liver disease (alcoholic *vs* nonalcoholic) \[OR (95%CI): 0.84 (0.25-2.79); *P* = 0.780\], bilirubin \[OR (95%CI): 0.81 (0.63-1.06); *P* = 0.123\], albumin \[OR (95%CI): 0.71 (0.28-1.83); *P* = 0.476\], or baseline HVPG \[OR (95%CI): 1.05 (0.91-1.21); *P* = 0.534\] in our study. Acute hemodynamic response to propranolol was based on a ≥ 10% reduction in HVPG from baseline in 96% of the patients and/or on a decrease in HVPG to \< 12 mmHg in 23.1% (Table [1](#T1){ref-type="table"}). The acute hemodynamic response was associated with a decrease of mean arterial pressure (MAP) that did not occur in nonresponders (% change MAP: -5.6% ± 12.2% *vs* 2.7% ± 9.7%, *P* \< 0.008) (Table [1](#T1){ref-type="table"}).

###### 

Baseline characteristics of patients

  **Variable[1](#T1FN1){ref-type="table-fn"}**                               **Acute responders, *n* = 52**   **Acute nonresponders, *n* = 24**   ***P* value**
  -------------------------------------------------------------------------- -------------------------------- ----------------------------------- ---------------
  Age in yr                                                                  57.8 ± 10.2                      57.1 ± 8.7                          0.764
  Sex (male)                                                                 40 (76.9)                        19 (79.2)                           1
  Body mass index                                                            28.6 ± 5.0                       28.5 ± 4.8                          0.918
  Associated diseases[2](#T1FN2){ref-type="table-fn"}                        34 (65.4)                        16 (66.7)                           1
  Regular medication                                                                                                                              
  Statins                                                                    3 (5.8)                          3 (12.5)                            0.373
  Metformin                                                                  10 (19.2)                        5 (20.8)                            1
  Antiplatelet agent                                                         7 (13.5)                         1 (4.2)                             0.423
  Anticoagulation                                                            2 (3.8)                          0 (0)                               1
  Etiology of liver disease[3](#T1FN3){ref-type="table-fn"}                                                                                       0.971
  Alcohol                                                                    34 (65.4)                        17 (70.8)                           0.794
  Hepatitis C                                                                4 (7.7)                          2 (8.3)                             1
  Alcohol + hepatitis C                                                      4 (7.7)                          2 (8.3)                             1
  Other                                                                      10 (19.2)                        3 (12.6)                            0.744
  Active alcoholism                                                                                                                               
  At first hemodynamic study                                                 11 (27.5)                        4 (20.0)                            0.753
  During follow-up                                                           3 (7.9)                          2 (10.5)                            1
  Active hepatitis C                                                                                                                              
  At first hemodynamic study                                                 8 (100)                          4 (100)                             1
  During follow-up                                                           4 (50)                           2 (50.0)                            1
  Esophageal varices                                                         49 (94.2)                        21 (87.5)                           0.310
  Small                                                                      3 (6.1)                          3 (14.3)                            0.355
  Large                                                                      46 (93.9)                        18 (85.7)                           
  Gastric varices                                                            3 (5.8)                          3 (12.5)                            0.373
  Red signs                                                                  10 (20.0)                        3 (13.6)                            0.742
  Hemoglobin in g/dL                                                         12.7 ± 2.1                       12.7 ± 2.2                          0.994
  Platelet count as × 10[3](#T1FN3){ref-type="table-fn"}/μL                  102 ± 45                         122 ± 53                            0.100
  Prothrombin time as INR                                                    1.36 ± 0.24                      1.39 ± 0.26                         0.685
  Bilirubin in mg/dL[3](#T1FN3){ref-type="table-fn"}                         1.7 ± 1.1                        2.8 ± 4.5                           0.235
  Albumin in g/dL[3](#T1FN3){ref-type="table-fn"}                            3.6 ± 0.6                        3.6 ± 0.6                           0.878
  Creatinine in mg/dL                                                        0.72 ± 0.24                      0.73 ± 0.24                         0.900
  Sodium in mEq/L                                                            139 ± 3                          138 ± 4                             0.108
  Hyponatremia (\< 135)                                                      3 (6.0)                          5 (20.8)                            0.103
  Ascites                                                                    31 (59.6)                        14 (58.3)                           1
  Refractory ascites                                                         1 (1.9)                          1 (4.2)                             0.535
  Hepatic encephalopathy                                                     8 (15.4)                         4 (16.7)                            1
  Spontaneous bacterial peritonitis                                          4 (7.7)                          0 (0)                               0.301
  Hepatocellular carcinoma                                                   3 (5.8)                          1 (4.2)                             1
  No previous decompensation                                                 21 (40.4)                        9 (37.5)                            1
  MELD                                                                       11.5 ± 3.2                       12.3 ± 4.4                          0.353
  Child-Pugh score                                                           6.5 ± 1.4                        6.7 ± 1.6                           0.560
  A/B/C, %                                                                   58/40/2                          50/42/8                             0.388
  Propranolol dose in acute test in mg                                       12.1 ± 2.4                       12.6 ± 2.8                          0.44
  Free hepatic venous pressure in mmHg                                       10.8 ± 4.3                       11.7 ± 4.7                          0.386
  Change from baseline, %                                                    +18.5 ± 23.5                     +3.4 ± 11.2                         \< 0.001
  Wedged hepatic venous pressure in mmHg                                     30.0 ± 5.4                       30.4 ± 5.5                          0.581
  Change from baseline, %                                                    -6.6 ± 5.3                       -1.2 ± 6.3                          \< 0.001
  Hepatic venous pressure gradient in mmHg[3](#T1FN3){ref-type="table-fn"}   18.8 ± 3.7                       18.7 ± 3.7                          0.854
  Change from baseline, %                                                    -17.8 ± 7.7                      -3.9 ± 5.6                          \< 0.001
  Decrease by \> 10%, %                                                      96.2                             0                                   \< 0.001
  Decrease to \< 12 mmHg, %                                                  23.1                             0                                   0.014
  Mean arterial pressure in mmHg                                             99 ± 9                           95 ± 11                             0.145
  Change from baseline, %                                                    -5.6 ± 12.2                      +2.7 ± 9.7                          0.008
  Heart rate as bpm                                                          78 ± 13                          81 ± 15                             0.315
  Change from baseline, %                                                    -18.8 ± 8.5                      -19.4 ± 7.3                         0.779
  Right atrial pressure in mmHg                                              7.0 ± 2.9                        7.3 ± 3.8                           0.712
  Change from baseline, %                                                    +51.4 ± 41.1                     +45.1 ± 45.3                        0.565
  Pulmonary arterial pressure in mmHg                                        18.3 ± 4.9                       17.8 ± 5.0                          0.700
  Change from baseline, %                                                    +18.6 ± 18.9                     +16.1 ± 14.9                        0.606
  Pulmonary wedge pressure in mmHg                                           11.8 ± 4.1                       11.4 ± 5.0                          0.711
  Change from baseline, %                                                    +28.3 ± 37.2                     +38.4 ± 54.9                        0.384

Quantitative variables were expressed as mean ± SD and qualitative variables as absolute value (proportion);

Associated diseases: hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, chronic renal disease;

Variables included in the multivariate analysis. INR: International normalized ratio; NSBB: Nonselective beta-blockers.

Chronic hemodynamic response in acute responders receiving traditional NSBB and in acute nonresponders receiving carvedilol
---------------------------------------------------------------------------------------------------------------------------

Twenty-seven patients (51.9%) in the traditional NSBB group and 13 (54.2%) in the carvedilol group had a second hemodynamic study performed after a mean ± SD duration of 26.3 ± 12.8 wk and 28.0 ± 18.8 wk, respectively. Among these patients, a chronic hemodynamic response was observed in 15 of 27 patients (55.6%) treated with traditional NSBB and in 9 of 13 patients (69.2%) treated with carvedilol (Fisher's exact test, *P* = 0.50). The misclassification rate (*i.e*. chronic nonresponse with traditional NSBB or chronic response with carvedilol) was not significantly different between groups (McNemar´s test, *P* = 0.664). In patients receiving traditional NSBB, the magnitude of the chronic change of HVPG was correlated with that observed after acute i.v. propranolol in the initial study (*r* = 0.59, *P* = 0.001; Figure [2](#F2){ref-type="fig"}). Most clinical, laboratory, endoscopic and hemodynamic parameters at baseline were similar in chronic responders and chronic nonresponders in the traditional NSBB and carvedilol groups, except for the alcoholic etiology of liver disease in the traditional NSBB group \[chronic response: 14/15 (93.3%) *vs* chronic nonresponse: 6/12 (50%), *P* = 0.024\] (Table [2](#T2){ref-type="table"}).

###### 

Characteristics of chronic hemodynamic responders and chronic nonresponders in each group

                                                        **Traditional NSBB**   **Carvedilol**                                            
  ----------------------------------------------------- ---------------------- ---------------- ----------- -------------- ------------- -------
  Age in yr                                             58.9 ± 8.3             57.8 ± 10.3      0.766       59.2 ± 9.2     57.3 ± 6.8    0.685
  Sex (male)                                            12 (80.0)              9 (75.0)         1           8 (88.9)       3 (75.0)      1
  Body mass index                                       28.8 ± 2.1             29.1 ± 4.3       0.795       30.5 ± 5.9     28.0 ± 3.6    0.370
  Associated diseases[2](#T2FN2){ref-type="table-fn"}   12 (80.0)              10 (83.3)        1           7 (77.8)       2 (50)        0.530
  Regular medication                                                                                                                     
  Statins                                               2 (13.3)               1 (8.3)          1           2 (22.2)       0 (0)         1
  Metformin                                             3 (20)                 2 (16.7)         1           1 (11.1)       2 (50.0)      0.203
  Antiplatelet agent                                    1 (6.7)                3 (25)           0.294       0 (0)          0 (0)         1
  Anticoagulation                                       1 (6.7)                1 (8.3)          1           0 (0)          0 (0)         1
  Etiology of liver disease                                                                     0.063                                    1
  Alcohol                                               14 (93.3)              6 (50.0)         0.024       8 (88.9)       4 (100)       1
  Hepatitis C                                           0 (0)                  2 (16.7)         0.188       0 (0)          0 (0)         1
  Alcohol + hepatitis C                                 0 (0)                  2 (16.7)         0.188       0 (0)          0 (0)         1
  Other                                                 1 (6.7)                2 (16.6)         0.569       1 (11.1)       0 (0)         1
  Active alcoholism                                     0 (0)                  1 (9.1)          0.440       1 (12.5)       1 (25.0)      1
  Active hepatitis C                                    0 (0)                  0 (0)            1           0 (0)          0 (0)         1
  Esophageal varices                                    14 (93.3)              11 (91.7)                    6 (66.7)       4 (100)       
  Small, %                                              0                      0                1           33.3           0             0.467
  Large, %                                              100                    100                          66.7           100           
  Gastric varices                                       1 (6.7)                1 (8.3)          1           3 (33.3)       0 (0.0)       0.497
  Red signs                                             3 (20.0)               1 (8.3)          0.605       1 (12.5)       1 (25.0)      1
  Baseline MELD                                         11.5 ± 2.9             11.0 ± 3.4       0.660       12.3 ± 6.3     12.8 ± 1.0    0.852
  Change from baseline, %                               -4.1 ± 14.2            0.8 ± 16.8       0.426       -0.8 ± 28.0    -7.9 ± 14.5   0.565
  Baseline Child-Pugh score                             6.7 ± 1.4              6.1 ± 1.1        0.225       6.8 ± 2.0      7.0 ± 0.0     0.753
  Change from baseline, %                               -3.0 ± 12.1            0.3 ± 9.9        0.465       -7.2 ± 13.7    0.0 ± 11.6    0.363
  Baseline Child-Pugh class A/B/C, %                    53/47/0                42/58/0          1           67/11/22       0/100/0       0.010
  Change from baseline A/B/C, %                         67/33/0                67/33/0          1           67/33/0        75/25/0       0.266
  Hemoglobin in g/dL                                    12.8 ± 2.1             14.0 ± 2.2       0.150       12.8 ± 2.0     14.5 ± 2.7    0.319
  Platelet count as × 10^3^/μL                          107 ± 35               86 ± 27          0.102       91 ± 32        114 ± 41      0.367
  Prothrombin time as INR                               1.37 ± 0.18            1.32 ± 0.15      0.498       1.28 ± 0.21    1.35 ± 0.04   0.358
  Bilirubin in mg/dL                                    1.3 ± 0.7              1.6 ± 0.8        0.349       1.57 ± 0.96    1.93 ± 1.19   0.619
  Albumin in g/dL                                       3.5 ± 0.5              3.7 ± 0.4        0.397       3.9 ± 0.4      3.5 ± 0.4     0.080
  Creatinine in mg/dL                                   0.72 ± 0.18            0.78 ± 0.16      0.415       0.71 ± 0.25    0.66 ± 0.05   0.590
  Sodium in mEq/L                                       140 ± 2                140 ± 3          0.342       139 ± 2        139 ± 2       0.638
  Ascites                                               9 (60.0)               6 (50.0)         0.707       5 (55.6)       4 (100)       0.228
  Hepatic encephalopathy                                4 (26.7)               0 (0)            0.106       0 (0)          1 (25.0)      0.308
  SBP                                                   3 (20.0)               0 (0)            0.231       0 (0)          0 (0)         1
  Hepatocellular carcinoma                              0 (0)                  0 (0)            1           0 (0)          0 (0)         1
  Hemodynamic variables                                                                                                                  
  Weeks between studies                                 24.2 ± 12.3            29.1 ± 13.4      0.327       26.2 ± 14.0    31.9 ± 29.4   0.732
  Propranolol dose in mg                                136 ± 111              165 ± 123        0.677                                    
  Nadolol dose in mg                                    87 ± 47                95 ± 21          0.659                                    
  Carvedilol dose in mg                                                                                     18.8 ± 12.5    14.1 ± 7.9    0.434
  FHVP in mmHg                                          10.0 ± 2.7             11.2 ± 2.4       0.250       11.9 ± 3.9     11.0 ± 2.1    0.583
  Change from baseline, %                               36.4 ± 62.6            -3.5 ± 30.4      0.054       10.4 ± 31.1    1.8 ± 8.4     0.458
  WHVP in mmHg                                          29.6 ± 2.5             29.0 ± 2.9       0.622       28.5 ± 5.7     31.1 ± 5.1    0.437
  Change from baseline, %                               -8.5 ± 15.9            0.7 ± 10.6       0.100       -9.5 ± 9.5     5.8 ± 9.2     0.034
  HVPG in mmHg                                          19.5 ± 2.9             17.9 (2.5)       0.126       16.4 ± 2.5     20.1 ± 3.2    0.100
  Change from baseline, %                               \- 26.0 ± 12.5         5.7 ± 17.7       \< 0.0001   -21.2 ± 12.8   -7.6 ± 13.3   0.012
  Decrease by \> 10%                                    15 (100)               0 (0)            \< 0.0001   8 (88.9)       0 (0)         0.007
  Decrease \< 12 mmHg                                   3 (20)                 0 (0)            0.231       4 (44.0)       0 (0)         0.228
  MAP in mmHg                                           99 ± 9                 98 ± 8           0.642       96 ± 12        97 ± 11       0.897
  Change from baseline, %                               -5.6 ± 7.3             0.3 ± 12.1       0.192       6.6 ± 17.8     -2.0 ± 7.7    0.273
  Heart rate as bpm                                     77 ± 11                77 ± 16          0.902       82 ± 11        76 ± 9        0.311
  Change from baseline, %                               -26.2 ± 12.5           -19.8 ± 14.9     0.265       -26.8 ± 10.6   -17.1 ± 7.7   0.102
  Right atrial pressure in mmHg                         6.4 ± 2.1              7.4 ± 2.3        0.264       8.4 ± 5.0      7.0 ± 1.4     0.458
  Change from baseline, %                               74.2 ± 82.3            24.1 ± 66.5      0.100       35.5 ± 97.2    23.2 ± 27.0   0.733
  PAP in mmHg                                           18.3 ± 4.2             17.9 ± 4.3       0.813       20.1 ± 4.8     17.5 ± 3.1    0.281
  Change from baseline, %                               35.3 ± 42.8            17.4 ± 27.6      0.222       -4.5 ± 18.7    27.5 ± 43.9   0.242
  PWP in mmHg                                           11.5 ± 3.3             11.8 ± 3.5       0.819       12.8 ± 5.3     12.0 ± 3.2    0.751
  Change from baseline, %                               50.9 ± 57.5            32.0 ± 61.2      0.417       5.5 ± 37.1     14.8 ± 10.8   0.506

Quantitative variables were expressed as mean ± standard deviation and qualitative variables as absolute value (proportion);

Associated diseases: hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, chronic renal disease. CR: Chronic responder; CNR: Chronic nonresponder; FHVP: Free hepatic venous pressure; HVPG: Hepatic venous pressure gradient; MAP: Mean arterial pressure; PAP: Pulmonary arterial pressure; PWP: Pulmonary wedged pressure; SBP: Spontaneous bacterial peritonitis; WHVP: Wedged hepatic venous pressure.

![Correlation between acute and chronic changes in HVPG in the traditional nonselective beta-blockers group. Among 52 patients, 27 had a second hemodynamic study after 26.3 ± 12.8 wk. HVPG: Hepatic venous pressure gradient.](WJCC-6-611-g002){#F2}

Development of decompensation in acute responders receiving traditional NSBB and in acute nonresponders receiving carvedilol
----------------------------------------------------------------------------------------------------------------------------

In patients with compensated cirrhosis, the actuarial probability of presenting their first decompensation at 1, 2 and 3 years was 0%, 13.7% and 26.1% in acute responders receiving traditional NSBB compared with 0%, 20% and 20% in acute nonresponders receiving carvedilol (*P* = 0.968) (Figure [3A](#F3){ref-type="fig"}). In patients with decompensated liver disease, the actuarial probability of presenting further hepatic decompensations at 1, 2 and 3 years was 21.2%, 26.1% and 40.9% in those receiving traditional NSBB compared with 21.2%, 50.0% and 50.0% in those receiving carvedilol (*P* = 0.525) (Figure [3B](#F3){ref-type="fig"}). No differences in the actuarial probability of presenting a decompensation were found either when patients with compensated and decompensated cirrhosis were pooled for analysis (*P* = 0.505) or when the 6 patients taking statins were excluded from the analysis (*P* = 0.319).

![Cumulative probability of decompensation in patients with previously compensated liver disease (A) and patients with a history of hepatic decompensation (B). Patients with acute response receiving traditional NSBB are represented by a continuous line, and acute nonresponders receiving carvedilol are represented by a dashed line. *P* value corresponds to log-rank test at the end of follow-up. NSBB: Nonselective beta-blockers.](WJCC-6-611-g003){#F3}

Twelve patients (23.1%) in the traditional NSBB group and 8 patients (33.3%) in the carvedilol group had a decompensation event during follow-up (*P* = 0.405), and most of them (*n* = 15, 75%) had decompensated liver disease at recruitment (Table [3](#T3){ref-type="table"}). The type of decompensation was similar between groups, being the most common hepatic encephalopathy and ascites (Table [3](#T3){ref-type="table"}). The actuarial probability of hepatic encephalopathy at 2 years was 12.7% and 26.8% (*P* = 0.358), whereas that of ascites was 11.1% and 23.8% (*P* = 0.362) in the traditional NSBB and carvedilol groups, respectively. The 2-year actuarial probability of variceal bleeding was 2.0% and 16.3%; this complication occurred in 2 patients in the traditional NSBB group and in 3 patients in the carvedilol group (*P* = 0.078).

###### 

Clinical outcomes during follow-up in patients with acute response treated with traditional nonselective beta-blockers and in patients without acute response treated with carvedilol

  **Variable[1](#T3FN1){ref-type="table-fn"}**              **Traditional NSBB, *n* = 52**   **Carvedilol, *n* = 24**   ***P* value**
  --------------------------------------------------------- -------------------------------- -------------------------- ---------------
  Decompensation (global)[2](#T3FN2){ref-type="table-fn"}   12 (23.1)                        8 (33.3)                   0.405
  First decompensation                                      3 (14.3)                         2 (22.2)                   0.622
  Further decompensation                                    9 (29.0)                         6 (40.0)                   0.514
  Portal hypertension-related bleeding                      2 (3.8)                          3 (12.5)                   0.318
  Ascites                                                                                                               
  Overall                                                   7 (13.5)                         4 (16.7)                   0.734
  *De novo* ascites                                         3 (5.8)                          1 (4.2)                    1
  Spontaneous bacterial peritonitis                         1 (1.9)                          2 (8.3)                    0.233
  Hepatorenal syndrome                                      1 (1.9)                          1 (4.2)                    0.535
  Hepatic encephalopathy                                                                                                
  Overall                                                   7 (13.5)                         5 (20.8)                   0.502
  *De novo* hepatic encephalopathy                          3 (5.8)                          4 (16.7)                   0.191
  Hepatocellular carcinoma (*de novo*)                      3 (6.1)                          0 (0)                      0.546
  Portal thrombosis                                         5 (9.6)                          3 (12.5)                   0.702
  Nonselective beta-blocker                                                                                             
  Propranolol dose, *n*/mg per day                          35 / 107.6                                                  
  Nadolol dose, *n*/mg per day                              17 / 83.5                                                   
  Carvedilol dose, *n*/mg per day                                                            24 / 9.2                   
  Chronic hemodynamic response                                                                                          
  Change from baseline HVPG, %                              -11.9 ± 21.8                     -12.2 ± 18.5               0.965
  ≥ 10% reduction in HVPG                                   15 (55.6)                        9 (69.2)                   0.503
  ≥ 20% reduction in HVPG                                   8 (29.6)                         4 (30.8)                   1
  Decrease to \< 12 mmHg                                    3 (11.1)                         4 (30.8)                   0.187
  Lost to follow-up, *n*/%                                  14 (26.9)                        3 (12.5)                   0.238
  Betablocker intolerance                                   6 (11.5)                         1 (4.2)                    0.421
  Change to carvedilol after second hemodynamic study       5 (7.7)                                                     
  Ceased follow-up                                          3 (5.8)                          2 (8.3)                    0.648

Quantitative variables were expressed as mean ± standard deviation and qualitative variables as absolute value (proportion);

Decompensation: Development of *de novo* or worsening ascites, hepatic encephalopathy, portal hypertension-related bleeding, hepatorenal syndrome or spontaneous bacterial peritonitis. The number of decompensation events in each group is lower than the total sum of each complication because some patients suffered more than one complication during follow-up. NSBB: Nonselective beta-blockers.

Serum bilirubin and albumin levels, Child-Pugh class and a history of hepatic encephalopathy were the only variables significantly associated with the risk of decompensation during follow-up in the univariate analysis (Table [4](#T4){ref-type="table"}). In a multivariate analysis including the latter two variables (serum bilirubin and albumin were not included since they are part of the Child-Pugh score) together with age and acute hemodynamic response, the only independent predictor of decompensation was a previous bout of overt hepatic encephalopathy (Table [4](#T4){ref-type="table"}).

###### 

Results of univariate and multivariate analyses for variables associated with risk of decompensation

  **Variables**                                                       **Univariable**     **Multivariable**                       
  ------------------------------------------------------------------- ------------------- ------------------- ------------------- ----------
  Age as per year increase                                            0.96 (0.91-1.01)    0.093               0.97 (0.92-1.02)    0.246
  Active alcoholism                                                   2.55 (0.71-9.16)    0.152                                   
  Size of varices                                                     1.71 (0.23-12.90)   0.602                                   
  Red signs                                                           1.89 (0.62-5.73)    0.262                                   
  MELD as per 1 point increase[1](#T4FN1){ref-type="table-fn"}        1.12 (0.99-1.26)    0.072                                   
  Child class                                                                             0.039                                   0.071
  B *vs* A                                                            2.66 (1.03-6.87)    0.044               2.39 (0.90-6.36)    0.081
  C *vs* A                                                            5.87 (1.20-28.63)   0.029               6.00 (1.09-32.97)   0.039
  Platelets as per 1 × 10^6^                                          1.00 (0.99-1.01)    0.641                                   
  Creatinine as per 1 mg/dL increase                                  0.17 (0.01-2.74)    0.209                                   
  Bilirubin as per 1 mg/dL increase[2](#T4FN2){ref-type="table-fn"}   1.21 (1.09-1.35)    \< 0.001                                
  Albumin as per 1 g/L increase[2](#T4FN2){ref-type="table-fn"}       0.43 (0.20-0.94)    0.035                                   
  INR as per 1 point increase                                         1.16 (0.20-6.56)    0.871                                   
  HVGP as per 1 mmHg increase                                         1.07 (0.96-1.20)    0.209                                   
  MAP as per 1 mmHg increase                                          0.98 (0.94-1.03)    0.497                                   
  Previous ascites[2](#T4FN2){ref-type="table-fn"}                    2.42 (0.88-6.65)    0.088                                   
  Previous hepatocellular carcinoma                                   2.44 (0.55-10.77)   0.240                                   
  Previous hepatic encephalopathy                                     7.29 (2.78-19.13)   \< 0.001            8.03 (2.76-23.37)   \< 0.001
  No previous decompensation[1](#T4FN1){ref-type="table-fn"}          0.42 (0.15-1.16)    0.093                                   
  Acute hemodynamic response                                          0.70 (0.29-1.71)    0.434               0.74 (0.28-1.95)    0.545
  Chronic hemodynamic response-10%                                    0.49 (0.13-1.83)    0.287                                   
  Chronic hemodynamic response-20%                                    0.24 (0.03-1.89)    0.174                                   

To avoid redundancy and due to a more significant association in the univariate analysis of the Child-Pugh class, MELD score and the absence of any previous decompensation were not included in the multivariate analysis;

History of ascites, serum bilirubin and albumin were not included in the multivariate analysis to avoid redundancy, since they are part of the Child-Pugh score. HR: Hazard ratio; HVPG: Hepatic venous gradient pressure; INR: International normalized ratio; MAP: Mean arterial pressure; MELD: Model of end-stage liver disease.

Survival
--------

Two patients (3.8%) in the traditional NSBB group and 1 patient (4.2%) in the carvedilol group underwent liver transplantation after 36.6, 16.6 and 4.8 mo of follow up, respectively. Six patients (11.5%) in the traditional NSSB group and one patient (4.2%) in the carvedilol group died during the follow up (*P* = 0.792). Most of them were liver-related deaths (traditional NSBB: 4 liver-related, 1 hepatocellular carcinoma, 1 no liver-related; carvedilol: 1 liver-related). In patients with compensated cirrhosis, the actuarial probability of mortality at 1, 2 and 3 years was 0%, 13.7% and 13.7% in the traditional NSBB group compared with 0%, 0% and 0% in the carvedilol group (*P* = 0.428) (Figure [4A](#F4){ref-type="fig"}). In patients with decompensated liver disease, the actuarial probability of mortality at 1, 2 and 3 years was 7.8%, 7.8% and 30.2% in those receiving traditional NSBB compared with 0%, 10.0% and 10.0% in those receiving carvedilol (*P* = 0.429) (Figure [4B](#F4){ref-type="fig"}). No differences in mortality were found either when patients with compensated and decompensated cirrhosis were pooled for analysis (*P* = 0.505) or when the 6 patients taking statins were excluded from the analysis (*P* = 0.409). No variables were associated with survival in the univariate analysis (Table [5](#T5){ref-type="table"}).

![Cumulative probability of transplant-free survival in patients with previously compensated liver disease (A) and patients with a history of hepatic decompensation (B). Patients with acute response receiving traditional NSBB are represented by a continuous line, and acute nonresponders receiving carvedilol are represented by a dashed line. *P* value corresponds to log-rank test at the end of follow-up. NSBB: Nonselective beta-blockers.](WJCC-6-611-g004){#F4}

###### 

Results of univariate analysis for variables associated with risk of death

  **Variables**                         **Univariable**          
  ------------------------------------- ------------------------ -------
  Age as per year increase              1.01 (0.93-1.09)         0.896
  Active alcoholism                     0.04 (0.00-2577625.31)   0.731
  Size of varices                       0.28 (0.03-2.55)         0.259
  MELD as per 1 point increase          0.91 (0.72-1.16)         0.448
  Child score as per 1 point increase   0.98 (0.59-1.67)         0.941
  Platelets as per 1 × 10^6^            0.98 (0.95-1.00)         0.088
  Creatinine as per 1 mg/dL increase    0.01 (0.00-4.55)         0.134
  Bilirubin as per 1 mg/dL increase     0.90 (0.59-1.39)         0.642
  Albumin as per 1 g/L increase         0.65 (0.17-2.43)         0.521
  INR as per 1 point increase           0.06 (0.00-4.39)         0.196
  HVGP as per 1 mmHg increase           1.12 (0.94-1.33)         0.195
  MAP as per 1 mmHg increase            1.01 (0.93-1.10)         0.791
  Previous ascites                      1.73 (0.34-8.96)         0.511
  Previous hepatocellular carcinoma     3.41 (0.40-29.45)        0.264
  Previous hepatic encephalopathy       2.72 (0.53-14.08)        0.233
  No previous decompensation            0.58 (0.11-3.01)         0.518
  Acute hemodynamic response            2.99 (0.36-24.91)        0.312
  Chronic hemodynamic response-10%      0.23 (0.02-2.57)         0.234
  Chronic hemodynamic response-20%      0.02 (0.00-427.79)       0.455

BMI: Body mass index; HVPG: Hepatic venous gradient pressure; INR: International normalized ratio; MAP: Mean arterial pressure; SBP: Spontaneous bacterial peritonitis.

DISCUSSION
==========

In patients with cirrhosis treated with traditional NSBB, the lack of acute hemodynamic response to i.v. propranolol has been consistently associated with a higher risk of decompensation and death\[[@B6],[@B7],[@B12]\]. Parallelly, beneficial effects of carvedilol have been shown in patients who do not achieve a chronic hemodynamic response with traditional NSBB\[[@B20]\]. None of these studies, however, evaluated the use of the acute hemodynamic response for deciding the initial treatment. In the present study, we evaluated for the first time the clinical impact of an acute hemodynamic response-guided protocol for the primary prophylaxis of variceal bleeding in which acute hemodynamic responders were treated with traditional NSBB and acute nonresponders with carvedilol. Importantly, the risk of decompensation and survival were similar in both groups, regardless of the history or type of decompensation.

The present results suggest that carvedilol improved the prognosis of patients who did not have a positive acute hemodynamic response to propranolol, as we did not find the expected association between the acute hemodynamic response and the risk of decompensation or mortality that has been consistently shown in prior studies. Indeed, the probabilities of decompensation and mortality were similar in acute responders and acute nonresponders regardless of the history of decompensation, and the only independent predictor of new decompensation was a previous bout of overt hepatic encephalopathy. The improved prognosis of acute nonresponders receiving carvedilol is further supported by the comparison of our results with previous studies. Importantly, our patients had similar or worse liver dysfunction compared with the patient population of prior studies, and the risk of decompensation in acute responders was also lower, probably due to the loss of follow-up of some high-risk patients (*i.e*. five chronic nonresponders to propranolol were changed to carvedilol)\[[@B6],[@B7],[@B12]\]. Despite these considerations, the patients receiving carvedilol in the present study presented a lower risk of decompensation than acute nonresponders treated with propranolol in other studies (2-year risk of variceal bleeding: 16.3% *vs* 23%-47%; 2-year risk of ascites: 23.8% *vs* 49%-67%)\[[@B6],[@B7],[@B12]\]. Remarkably, the mortality rate was also substantially lower than the 23% mortality reported by Villanueva et al\[[@B6]\]. Although a control group of acute nonresponders treated with traditional NSBB would be needed for a definitive conclusion, our results together with those of prior studies strongly suggest that carvedilol improved the long-term outcome of acute nonresponders.

The ability of the acute response to i.v. propranolol for identifying a subgroup of patients with a higher risk of decompensation and death is well-established\[[@B6],[@B12]\]. In addition, the test is currently considered the most accurate predictor of the chronic hemodynamic response to traditional NSBB\[[@B1],[@B2]\]. Similar to previous studies, no other clinical, laboratory, or endoscopic variables at baseline were able to predict neither the acute nor the chronic hemodynamic response in our study\[[@B6],[@B12]\]. Of note, we observed an association between a positive acute response and a decrease of MAP. Whether the acute change in MAP could help to identify acute hemodynamic responders would require further investigation, as a decrease in MAP has been observed in some studies\[[@B19]\] but not in others\[[@B6]\]. Based on its unique predictive value, recent studies have proposed using the acute hemodynamic response to i.v. propranolol to guide therapy\[[@B13],[@B14]\]. Such an approach, however, has never been formally evaluated in primary prophylaxis of variceal bleeding. The results of our study provide valuable information in this regard from real clinical practice, indicating that the early identification of acute nonresponders and their subsequent treatment with carvedilol may significantly improve the prognosis of these patients. We did not observe any particular adverse effects, including renal function, in patients treated with carvedilol. In addition to its role for guiding therapy, the inclusion of the acute hemodynamic test in the design of future randomized trials of primary prophylaxis of variceal bleeding would also be important for avoiding selection bias. Contrary to current guidelines that recommend that either of type of beta-blocker can be used\[[@B1],[@B2],[@B16]\], our results suggest that carvedilol should become the beta-blocker of choice in centers with no available hepatic hemodynamic testing until adequate clinical trials are performed.

The high proportion of acute nonresponders (69.2%) that achieved a chronic hemodynamic response with carvedilol and the correlation between the magnitude of HVPG changes in the acute and the chronic hemodynamic responses are other relevant findings from our study that support previous observations\[[@B6],[@B18],[@B20]\]. Accordingly, Reiberger et al\[[@B20]\] recently reported that up to 56% of patients who had no chronic hemodynamic response to propranolol were able to achieve a hemodynamic response after switching to carvedilol, supporting the efficacy of carvedilol in this patient population. The enhanced effects of carvedilol for reducing portal pressure might be responsible for the favorable outcome of acute nonresponders found in our study. The lack of association between the chronic response to NSBB and the risk of decompensation may be related to a low statistical power as well as to the late performance of the second hemodynamic study. Indeed, a late evaluation of the hemodynamic response has been associated with a poorer accuracy in predicting outcome because some chronic nonresponders might benefit from nonhemodynamic effects of NSBB (*e.g*., reduction of bacterial translocation) leading to a favorable outcome despite such nonresponse\[[@B1]\].

The retrospective and single-center design of our study might account for potential selection bias, but the baseline characteristics of our patients were equally distributed between groups and comparable to those of previous studies\[[@B6],[@B12]\], and they were well followed and studied. Importantly, confounding biases such as alcohol withdrawal, clearance of hepatitis C and relevant concomitant treatments were thoroughly recorded and there were no differences between groups. Noteworthy, excluding 6 patients that received statins, which have been reported to influence portal pressure and decompensations, did not alter the main results\[[@B21]\]. Furthermore, we performed multivariate analyses and compared the risk of decompensation separately in patients with compensated and decompensated cirrhosis to avoid the well-known bias of pooling both groups of patients in portal hypertension research\[[@B6],[@B12]\]. Remarkably, the present study is one of the largest series involving the evaluation of the acute hemodynamic response, and the first to evaluate its usefulness for guiding therapy in real clinical practice. Based on the risk of decompensation of acute and nonacute responders treated with traditional NSBB reported in prior studies\[[@B6],[@B7],[@B12]\], the sample size of our study had enough statistical power to make adequate comparisons of the main endpoint. Indeed, the estimated sample size for patients with compensated cirrhosis, using the arcsin square root transformation, would be of 17 acute responders and 9 acute nonresponders, computing a risk of decompensation at 2 years in acute responders of 20%, a risk ratio of 3, a ratio of acute responders/nonresponders of 2, an alpha error of 0.05 and beta error of 0.20. With similar settings and even a lower risk ratio of 2.5 in patients with decompensated cirrhosis, the required sample size would be of 29 acute responders and 15 nonresponders. It is still possible, however, that the statistical power was limited for some analyses. For instance, the 2-year actuarial probability of variceal bleeding might have been different between groups had the sample size been greater. It should also be recognized that our results may not be generalized to patients with grades of liver dysfunction different from those of our study population.

In conclusion, the early identification of acute nonresponders and their treatment with carvedilol resulted in risks of decompensation and death that were comparable to those of acute responders treated with propranolol. These findings suggest that carvedilol improved the long-term outcome of acute nonresponders, presumably by its greater effects on reducing portal pressure, and should be the preferred choice over NSBB for primary prophylaxis of variceal bleeding when hemodynamic testing is not available.
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ARTICLE HIGHLIGHTS
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Research background
-------------------

Traditional nonselective beta-blockers (NSBBs) (*i.e*. propranolol and nadolol) and carvedilol are valid first-line treatments in patients starting primary prophylaxis of variceal bleeding. Although no clinical trial has adequately compared their efficacy head-to-head, several randomized controlled trials and a meta-analysis have shown that carvedilol is more effective in reducing portal pressure. NSBB-induced reductions in hepatic venous pressure gradient (HVPG) \> 10% from baseline have been associated with a lower risk of decompensation and death. The acute hemodynamic test (*i.e*. HVPG response after 20 min of the intravenous injection of 0.15 mg/kg propranolol) has been proposed as a valid and more cost-effective alternative to separate HVPG procedures. Supporting this notion, recent studies in patients treated with traditional NSBB showed that the risk of decompensation was lower in those who had an acute response than in those who were acute nonresponders. The acute test also predicted the chronic hemodynamic response.

Research motivation
-------------------

Since the acute test enables the earlier identification of chronic nonresponders to traditional NSBB and carvedilol has a greater efficacy for reducing portal pressure, this test could guide the type of NSBB to be used in patients starting primary prophylaxis of variceal bleeding.

Research objectives
-------------------

The primary endpoint was development of first or further decompensation of cirrhosis. Secondary endpoints included death from any cause, association between acute and chronic hemodynamic response, and baseline clinical and laboratory variables related to the acute hemodynamic response.

Research methods
----------------

We retrospectively reviewed all patients starting primary prophylaxis of variceal bleeding following an acute hemodynamic response-guided protocol. Acute or chronic hemodynamic response was defined as a decrease in HVPG to \< 12 mmHg or as a ≥ 10% reduction in HVPG from baseline. According to our institutional protocol, 52 acute responders to intravenous propranolol were treated with traditional NSBB (*i.e*. propranolol or nadolol) and 24 acute nonresponders received carvedilol. A second hemodynamic study was performed in 27 and 13 patients, respectively. Follow-up data (*i.e*. medical history, laboratory values, imaging tests and treatment compliance) were recorded in each visit (*i.e*. within 1 mo after the performance of the baseline hemodynamic study, and every 3-6 mo thereafter).

Research results
----------------

The risk of first or further decompensation was similar in both groups at 1, 2 and 3 years of follow-up. A previous episode of hepatic encephalopathy was the only independent predictor of decompensation. Mortality rates were also similar between groups. No clinical, laboratory, or endoscopic variables at baseline were able to predict neither the acute nor the chronic hemodynamic response. A high proportion of acute nonresponders (69.2%) achieved a chronic hemodynamic response with carvedilol and there was a strong correlation between the acute and chronic changes in HVPG in the traditional NSBB group.

Research conclusions
--------------------

The early identification of acute nonresponders and their treatment with carvedilol resulted in risks of decompensation and death that were comparable to those of acute responders treated with propranolol. These findings suggest that carvedilol improved the long-term outcome of acute nonresponders, presumably by its greater effects on reducing portal pressure, and should be the preferred choice over NSBB for primary prophylaxis of variceal bleeding when hemodynamic testing is not available.

Research perspectives
---------------------

The design of our study cannot definitively conclude that carvedilol should become the beta-blocker of choice in patients starting primary prophylaxis of variceal bleeding. In order to confirm this possibility, a randomized controlled trial with a control group of acute nonresponders treated with traditional NSBB would be needed.
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